News

Mediscience Technology, a developer of minimally invasive autofluorescent-based technology for early detection of cancer, has expanded its technology platform with the completion of the acquisition of SensiVida Medical

Financial Data Gross margin stood at 53.4% of net sales, versus 53.2% in 2007, while gross profit amounted to EUR593 million compared with EUR566 million the year before.

Schering-Plough has received the FDA approval for new labeling of Pegintron and Rebetol combination therapy for treating chronic hepatitis C in patients three years of age and older

The new location offers room for anticipated growth and establishes a permanent headquarters for the company’s North America Region and US subsidiary, Karl Storz Endoscopy-America. The move is

innovatis will become a fully-integrated part of Roche Applied Science, a global business area of the diagnostic division of Roche. The company will continue to develop and market

pSivida, a drug delivery company, has reported encouraging interim 12-month safety and efficacy results from the first human pharmacokinetic study of Iluvien. The study is being conducted by

Sigma-Aldrich’s expansion of operations in Chile is part of the company’s strategic plan to accelerate growth in Canada, Asia Pacific and Latin America to 25% of corporate sales

In addition, NeoMatrix announced a current oversubscription of the C2 round totaling $1.2 million. In order to accommodate those investors who are part of this $1.2 million oversubscription

Astellas also intends to withdraw a related lawsuit in the Delaware Chancery Court against CV Therapeutics and its directors. Astellas said that it does not see value for